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It has come the publisher’s attention that the original ver-
sion of this article [1] unfortunately contained an error. 
In Table 3, first column, the FcγRIIA 131 H>R genotypes 
were incorrectly labelled. In particular, V/V should have 
read H/H, V/F should have read H/R and F/F should 
have read R/R. Please note that this correction does not 
change the genotype numerical values of FcγRIIA poly-
morphism. The correct Table  3 has been published as 
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Table 1 Genotypic and allelic frequencies of FcγRIIIA and FcγRIIA polymorphisms in breast cancer patients and healthy 
controls
Genotyping of FcγRIIIA 158V>F was performed by a newly developed PSQ method after pre-amplification of FcγRIIIA gene. Genotyping of FcγRIIA 131H>R 
was performed by T-ARMS PCR and SBT. Conventionally, the 158V>F variant corresponds to the G>T SNP [i.e. guanine corresponding to valine (V) and thymine 
corresponding to phenylalanine (F)] and the 131H>R SNP corresponds to the A>G SNP [i.e. adenine corresponding to histidine (H) and guanine corresponding to 
arginine (R)]
Comparison of FcγR genotypic and allelic frequencies between patients and control subjects was estimated using the Pearson’s χ2  test (P* value) and the Fisher’s test 
(P° value), respectively. Statistical significance: P < 0.05
NEO neoadjuvant, MTS metastatic, CTR controls, HWE Hardy–Weinberg equilibrium. HWE was tested by the Pearson’s χ2 test (P < 0.05 indicates lack of HWE)













FcγRIIIA 158V>F FcγRIIIA 158V>F
 V/V 4 (26.7) 3 (30.0) 6 (18.2) 0.741  V 13 (0.43) 8 (0.40) 26 (0.39) 0.934
 V/F 5 (33.3) 2 (20.0) 14 (42.4)  F 17 (0.57) 12 (0.60) 40 (0.60)
 F/F 6 (40.0) 5 (50.0) 13 (39.4)
 HWE P = 0.213 P = 0.065 P = 0.522
FcγRIIA 131H>R FcγRIIA 131H>R
 H/H 3 (20.0) 4 (40.0) 9 (27.3) 0.499  H 14 (0.47) 10 (0.50) 35 (0.53) 0.843
 H/R 8 (53.3) 2 (20.0) 17 (51.5)  R 16 (0.53) 10 (0.50) 31 (0.47)
 R/R 4 (26.7) 4 (40.0) 7 (21.2)
 HWE P = 0.782 P = 0.058 P = 0.845
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